Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of ALLN-346 in Healthy Volunteers
NCT04829435Phase 1Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperuricemia and gout comparing ALLN-346 with Placebo (2 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events at 28 days. Started Apr 2021; status: completed.
02
Drugs
ALLN-346
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT04829435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829435.